AAAAAA
Results: 1-25/33
Authors:
Berenson, JR
Citation: Jr. Berenson, Advances in the biology and treatment of myeloma bone disease, AM J HEAL S, 58(22), 2001, pp. S16-S20
Authors:
Berenson, JR
Vescio, RA
Rosen, LS
VonTeichert, JM
Woo, M
Swift, R
Savage, A
Givant, E
Hupkes, M
Harvey, H
Lipton, A
Citation: Jr. Berenson et al., A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases, CLIN CANC R, 7(3), 2001, pp. 478-485
Authors:
Berenson, JR
Citation: Jr. Berenson, Painful osteoblastic metastases: The role of nuclear medicine - The Silberstein article reviewed, ONCOLOGY-NY, 15(2), 2001, pp. 170
Authors:
Beksac, M
Ma, M
Akyerli, C
DerDanielian, M
Zhang, L
Liu, J
Arat, M
Konuk, N
Koc, H
Ozcelik, T
Vescio, R
Berenson, JR
Citation: M. Beksac et al., Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM), LEUKEMIA, 15(8), 2001, pp. 1268-1273
Authors:
Berenson, JR
Ma, HM
Vescio, R
Citation: Jr. Berenson et al., The role of nuclear factor-kappa B in the biology and treatment of multiple myeloma, SEMIN ONCOL, 28(6), 2001, pp. 626-633
Authors:
Berenson, JR
Citation: Jr. Berenson, Zoledronic acid in cancer patients with bone metastases: Results of phase I and II trials, SEMIN ONCOL, 28(2), 2001, pp. 25-34
Authors:
Berenson, JR
Citation: Jr. Berenson, New advances in the biology and treatment of myeloma bone disease, SEM HEMATOL, 38(2), 2001, pp. 15-20
Authors:
Berenson, JR
Rosen, LS
Howell, A
Parter, L
Coleman, RE
Morley, W
Dreicer, R
Kuross, SA
Lipton, A
Seaman, JJ
Citation: Jr. Berenson et al., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases - A double-blind, randomized dose-response study, CANCER, 91(7), 2001, pp. 1191-1200
Authors:
Berenson, JR
Rosen, LS
Howell, A
Porter, L
Coleman, RE
Morley, W
Citation: Jr. Berenson et al., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study (vol 91, pg 1191, 2001), CANCER, 91(10), 2001, pp. 1956-1956
Authors:
Berenson, JR
Vescio, R
Henick, K
Nishikubo, C
Rettig, M
Swift, RA
Conde, F
Von Teichert, JM
Citation: Jr. Berenson et al., A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease, CANCER, 91(1), 2001, pp. 144-154
Authors:
Berenson, JR
Vescio, R
Henick, K
Nishikubo, C
Rettig, M
Swift, RA
Conde, F
Von Teichert, JM
Citation: Jr. Berenson et al., A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease, CANC CYTOP, 91(1), 2001, pp. 144-154
Authors:
Ma, HJ
Sjak-Shie, NN
Vescio, RA
Kaminsky, M
Mikail, A
Pold, M
Parker, K
Beksac, M
Belson, D
Moss, TJ
Wu, CH
Zhou, J
Zhang, L
Chen, G
Said, JW
Berenson, JR
Citation: Hj. Ma et al., Human herpesvirus 8 open reading frame 26 and open reading frame 65 sequences from multiple myeloma patients: A shared pattern not found in Kaposi's sarcoma or primary effusion lymphoma, CLIN CANC R, 6(11), 2000, pp. 4226-4233
Authors:
Sjak-Shie, NN
Vescio, RA
Berenson, JR
Citation: Nn. Sjak-shie et al., Recent advances in multiple myeloma, CURR OPIN H, 7(4), 2000, pp. 241-246
Authors:
Berenson, JR
Sjak-Shie, NN
Vescio, RA
Citation: Jr. Berenson et al., The role of human and viral cytokines in the pathogenesis of multiple myeloma, SEM CANC B, 10(5), 2000, pp. 383-391
Authors:
Berenson, JR
Citation: Jr. Berenson, The Olson/Pienta commentary reviewed, ONCOLOGY-NY, 14(9), 2000, pp. 1366-1367
Authors:
Hillner, BE
Ingle, JN
Berenson, JR
Janjan, NA
Albain, KS
Lipton, A
Yee, G
Biermann, JS
Chlebowski, RT
Pfister, DG
Citation: Be. Hillner et al., American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer, J CL ONCOL, 18(6), 2000, pp. 1378-1391
Authors:
Berenson, JR
Citation: Jr. Berenson, Myeloma - The therapeutic challenge, MED KLIN, 95(10), 2000, pp. A19-A21
Authors:
Vescio, RA
Wu, CH
Zheng, L
Sheen, D
Ma, H
Liu, J
Stewart, AK
Ballester, O
Noga, SJ
Rugo, H
Freytes, C
Stadtmauer, E
Sahebi, F
Tarantolo, S
Stiff, P
Schiller, GJ
White, M
Jacobs, C
DiPersio, J
Anderson, KC
Berenson, JR
Citation: Ra. Vescio et al., Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograftproducts from multiple myeloma patients, BONE MAR TR, 25(2), 2000, pp. 153-160
Authors:
Pold, M
Pold, A
Ma, HJ
Sjak-Shie, NN
Vescio, RA
Berenson, JR
Citation: M. Pold et al., Cloning of the first invertebrate MAGE paralogue: an epitope that activates T-cells in humans is highly conserved in evolution, DEV COMP IM, 24(8), 2000, pp. 719-731
Authors:
Douek, DC
Vescio, RA
Betts, MR
Brenchley, JM
Hill, BJ
Zhang, L
Berenson, JR
Collins, RH
Koup, RA
Citation: Dc. Douek et al., Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution, LANCET, 355(9218), 2000, pp. 1875-1881
Authors:
Ablashi, DV
Chatlynne, L
Thomas, D
Bourboulia, D
Rettig, MB
Vescio, RA
Viza, D
Gill, P
Kyle, RA
Berenson, JR
Whitman, JE
Citation: Dv. Ablashi et al., Lack of serologic association of human herpesvirus-8 (KSHV) in patients with monoclonal gammopathy of undetermined significance with and without progression to multiple myeloma, BLOOD, 96(6), 2000, pp. 2304-2306
Authors:
Dilworth, D
Liu, L
Stewart, AK
Berenson, JR
Lassam, N
Hogg, D
Citation: D. Dilworth et al., Germline CDKN2A mutation implicated in predisposition to multiple myeloma, BLOOD, 95(5), 2000, pp. 1869-1871
Authors:
Berenson, JR
Citation: Jr. Berenson, Management of myeloma bone disease, CANCER AND THE SKELETON, 2000, pp. 215-230
Authors:
Lipton, A
Berenson, JR
Citation: A. Lipton et Jr. Berenson, Bisphosphonate treatment of lytic bone metastases, DRUG AGING, 14(4), 1999, pp. 241-246
Authors:
Sjak-Shie, NN
Vescio, RA
Berenson, JR
Citation: Nn. Sjak-shie et al., The role of human herpesvirus-8 in the pathogenesis of multiple myeloma, HEMAT ONCOL, 13(6), 1999, pp. 1159